

REVIEW ARTICLE

α -Mangostin in Diabetic Wound Healing: Roles of Growth Factors and Endothelial Dysfunction

Melonney Patrick^{1*}, Wan Najwa Wan Mohd Zohdi², Suhaila Abd.Muid^{3,5}, Effat Omar^{4,5}

¹ Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah (UMS), 88400 Kota Kinabalu, Sabah, Malaysia

² Department of Rehabilitation Medicine, Faculty of Medicine, Universiti Teknologi MARA Sungai Buloh, 47000 Sungai Buloh, Selangor, Malaysia,

³ Department of Biochemistry & Molecular Medicine, Faculty of Medicine, Universiti Teknologi MARA Sungai Buloh, 47000 Sungai Buloh, Selangor, Malaysia,

⁴ Department of Pathology, Faculty of Medicine, Universiti Teknologi MARA Sungai Buloh, 47000 Sungai Buloh, Selangor, Malaysia,

⁵ Cardiovascular Advancement and Research Excellence Institute (CARE Institute), Universiti Teknologi MARA Sungai Buloh, 47000 Sungai Buloh, Selangor, Malaysia.

* Corresponding author's email: melonney@ums.edu.my

Received: 30 September 2025

Accepted: 15 December 2025

Published: 13 July 2026

DOI: <https://doi.org/10.51200/bjms.v20iSuppl.8010>

Keywords: *BAlpha-mangostin, Diabetic wound healing, Endothelial dysfunction, Growth factors*



Borneo Journal of Medical Sciences © 2025 The Authors is licensed under CC BY-NC 4.0 (<https://creativecommons.org/licenses/by-nc/4.0/>)

ABSTRACT

Diabetic foot ulcers (DFUs) represent one of the most debilitating complications of diabetes mellitus, largely driven by impaired wound healing processes, endothelial dysfunction, and dysregulated growth factor activity. Normal wound repair is orchestrated by a coordinated sequence of cellular and molecular events involving macrophages, fibroblasts, and endothelial cells, with growth factors such as PDGF, VEGF, TGF- β , bFGF, and CTGF playing central roles. In diabetic conditions, however, hyperglycemia-induced oxidative stress, reduced nitric oxide availability, and chronic inflammation disrupt these pathways, leading to delayed angiogenesis and poor tissue regeneration. Natural products have emerged as promising alternatives for chronic wound management, owing to their antioxidant, anti-inflammatory, and pro-angiogenic properties. Among these, α -mangostin, the predominant xanthone in the mangosteen (*Garcinia mangostana*) pericarp, has demonstrated potent anti-inflammatory and proliferative effects in vitro, accelerating fibroblast migration and suppressing cytokines such as IL-6 and IL-8. While most studies to date have focused on normal wound models, evidence suggests that α -mangostin may also modulate endothelial function and growth factor signaling under diabetic conditions. This review synthesizes current knowledge on growth factor regulation, endothelial dysfunction, and the therapeutic potential of α -mangostin in diabetic wound healing. Understanding

these mechanisms may provide a foundation for developing cost-effective, locally sourced, natural product-based therapies to reduce the clinical and economic burden of DFUs.

INTRODUCTION

Diabetes mellitus is a chronic and multifactorial metabolic disorder marked by persistent hyperglycaemia, resulting from impaired insulin secretion, insulin resistance, or both. Prolonged hyperglycaemia contributes to progressive damage across multiple organ systems, ultimately leading to complications such as blindness, kidney failure, and cardiovascular disease (Maurya, Varma, Chaurasia, Vishwakarma, & Reviews, 2019; Pan, Kaminga, Wen, Acheampong, & Liu, 2019).

Malaysia is also experiencing an alarming rise in diabetes prevalence. The proportion of Malaysian adults with the disease increased from 8.3% in 1996 to 14.9% in 2006, and further to 18.3% in 2019. By 2025, projections indicate that nearly 7 million Malaysian adults will be affected (Akhtar et al., 2022; Ganasegeran et al., 2021). This rapid increase prompted the Ministry of Health to launch a nationwide healthy lifestyle campaign aimed at strengthening screening and management of diabetes in both primary and secondary healthcare settings, accompanied by the establishment of a national steering committee (Yun et al., 2007). Figure 1 shows the global trend of diabetes.

If diabetes is not adequately controlled, patients may develop chronic complications that progress gradually over time. These complications are generally classified into macrovascular, microvascular, and immunosuppressive categories. Macrovascular complications include cerebrovascular, cardiovascular, and peripheral vascular diseases, while microvascular complications give rise to diabetic nephropathy, retinopathy, and neuropathy. Immunosuppression, on the other hand, predisposes individuals to

diabetic foot ulcers, impaired wound healing, and a heightened risk of infection. Such conditions are frequently observed among the diabetic population in Malaysia. In particular, the interplay of immunosuppression, peripheral vascular disease, microangiopathy, neuropathy, and weakened immune responses significantly contributes to poor wound healing and the development of diabetic foot ulcers (DFU), which may ultimately progress to gangrene and necessitate amputation (Deshpande, Harris-Hayes, & Schootman, 2008; Ganasegeran et al., 2020).




Figure 1: Global Diabetes Trends: In 2021, 537 million adults (20-79 years old) had diabetes, projected to reach 643 million by 2030 and 783 million by 2045. A concerning rise in diabetes cases worldwide. Reproduced from: International Diabetes Federation (IDF) (Magliano, Boyko, & Atlas, 2021).

Diabetic foot ulcer (DFU) is a serious and debilitating complication of poorly controlled and long-standing diabetes, typically manifesting as ulcerations on the plantar surface of the foot. Owing to its high morbidity, often associated with severe infections such as osteomyelitis and the risk of lower-limb amputation, it is crucial to address and treat the underlying causes of DFU promptly and effectively (Raja, Maturana, Kayali, Khouzam, & Efevbokhan, 2023). Diabetic wounds exhibit several abnormalities indicative of localized endothelial dysfunction. Evidence from experimental diabetic animal models of acute cutaneous wound healing has shown a reduction in nitric oxide (NO)

expression, which correlates with impaired healing characterized by diminished collagen deposition and reduced wound tensile strength. Additionally, altered expression of both endothelial and inducible nitric oxide synthase (NOS) has been reported in diabetic wound tissues compared to those of non-diabetic controls (Laing, Hanson, Chan, & Bouchier-Hayes, 2007).

Numerous studies have demonstrated that natural products possessing anti-inflammatory, antioxidant, antibacterial, and collagen-promoting properties contribute positively to wound healing (Thakur, Jain, Pathak, Sandhu, & medicine, 2011).

The phytochemical constituents of medicinal plants are known to enhance key processes such as tissue remodeling, epithelial regeneration, and angiogenesis (Hsu, 2005; Thangapazham, Sharad, & Maheshwari, 2016; Vanden Berghe & Haegeman, 2010). Such effects are particularly valuable in the management of chronic wounds, including diabetic foot ulcers, which often demand costly and prolonged treatment, imposing a significant socio-economic burden on both patients and healthcare systems (Shearer, Scuffham, Gordoio, & Oglesby, 2003; Wild, Roglic, Green, Sicree, & King, 2004).

Given this challenge, the search for novel therapeutic agents and a deeper understanding of their underlying mechanisms remain essential (Jivad, Bahmani, & Asadi-Samani, 2016; Naji, Zarei, Pourjabali, & Mohammadi, 2017).

Among natural products, mangosteen has attracted increasing scientific interest as a potential candidate for diabetic wound healing. Recent years have witnessed a growing number of publications highlighting its role in accelerating wound repair. In this context, the present study specifically investigates the effect of α-mangostin, the most abundant xanthone derived from the mangosteen

pericarp on wound healing using an in vitro diabetic wound model (Obolskiy, Pischel, Siriwatanametanon, Heinrich, & Derivatives, 2009; Yang et al., 2017).

Previous studies have reported the positive effects of α-mangostin on wound-healing processes, demonstrating its ability to modulate key growth factors and matrix-regulating enzymes. In the present study, α-mangostin at 2.5 µg/mL markedly increased the secretion of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), while reducing matrix metalloproteinase-9 (MMP-9) levels compared to glucose-induced controls. These findings further support earlier evidence suggesting that α-mangostin enhances angiogenesis and tissue regeneration through the up-regulation of PDGF and VEGF signaling pathways and inhibition of excessive matrix degradation (Patrick, Zohdi, Abd Muid, & Omar, 2024).

In this review, we discuss the roles of growth factors and endothelial dysfunction in diabetic wound healing and highlight the novel therapeutic potential of α-mangostin based on its reported in vitro mechanisms.

Diabetic foot ulcers

The term 'diabetic foot ulcers' (DFU) typically refers to a non-healing, chronic foot ulceration with superimposed infection (Craus, Mula, & Coppini, 2023). It is estimated that 2 to 3% of patients with diabetes mellitus have an active foot ulcer, with the lifetime risk of developing a foot ulcer as high as 25% (Lim, Ng, & Thomas, 2017). DFU is currently considered to be one of the most significant causes of morbidity and the primary reason for hospitalisation in diabetic patients (Shahbazian, Yazdanpanah, & Latifi, 2013).

Individuals with a history of lower extremity amputation, previous foot ulcers, foot deformities, peripheral vascular disease, or diabetic nephropathy, particularly those undergoing dialysis are at greater risk of

developing diabetic foot ulcers (DFU) (Aumiller & Dollahite, 2015; Panneerselvam, Vijayakumar, Raja, & Venkatesan, 2021). Walking barefoot or without appropriate footwear or foot protection further increases this risk (Chavan, 2018). A meta-analysis involving 542 patients with DFU reported that 46 cases were associated with peripheral arterial disease (PAD) as a contributing factor (Z. H. Huang et al., 2019). Similarly, in a study by Yazdanpanah et al., several clinical features were identified as significant risk factors: among 566 diabetic patients, 474 presented with foot dryness, 52 with foot deformities, and 12 with a history of foot ulcers or amputations. These findings emphasise the critical need to address and manage modifiable risk factors to reduce the incidence of DFU among diabetic individuals (Yazdanpanah et al., 2018).

A diabetic foot ulcer (DFU) is defined as a full-thickness wound that penetrates through the dermis, vascular, and collagen-rich layer of the skin occurring below the ankle. Once ulceration develops, the affected area becomes highly vulnerable to infection (Bakker et al., 2016; Jalilian, Sarbarzeh, Oubari, targets, & therapy, 2020). Multiple factors, including inadequate tissue perfusion (oxygen delivery), bacterial infection, malnutrition, and poor glycaemic control, can impair the wound healing process by disrupting the body's ability to repair and regenerate damaged tissue (Ontario, 2017). Evidence indicates that approximately 78% of individuals with DFU exhibit microvascular complications associated with peripheral arterial disease (PAD), primarily due to endothelial cell dysfunction, which reduces blood supply and further predisposes to ulcer formation (Baig et al., 2022). These conditions demand prompt medical intervention to prevent progression and worsening of DFU if left untreated.

Normal wound healing

Normal wound healing is defined by the body's ability to repair tissue through a well-organised and efficient process that restores

both structure and function. Typically, uncomplicated wounds heal within 5 to 10 days. This natural repair mechanism proceeds through four overlapping but distinct phases: hemostasis (blood clotting), inflammation, proliferation (involving angiogenesis, granulation, and re-epithelialisation), and tissue remodelling (Salazar-Gómez & Alonso-Castro, 2022).

Each phase has a specific duration, cellular activity, extracellular mediators, and growth factors that act as signals, suppressors, or promoters of healing. The acute inflammatory response plays a crucial role at the beginning of tissue repair. It not only initiates blood clotting to minimise blood loss but also helps clear bacteria and foreign debris from the wound, thereby creating the conditions necessary for healing to proceed (Demidova-Rice, Hamblin, Herman, & care, 2012; Slavich & Irwin, 2014).

Once the inflammatory phase subsides, the wound enters the proliferative stage, marked by fibroblast proliferation, angiogenesis, and re-epithelialisation of the wound surface. This is followed by the remodelling phase, characterised by reduced angiogenesis and increased deposition of collagen and extracellular matrix components. During this stage, the new tissue gradually gains strength and flexibility, signalling the near completion of the healing process (Nussbaum et al., 2015). Cells such as macrophages, endothelial cells, and fibroblasts actively participate throughout these stages by secreting cytokines and growth factors including interleukin-6 (IL-6), tumour necrosis factor- α (TNF- α), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). These mediators establish a complex signalling network that coordinates interactions among the various cell types involved in healing. Endothelial cells, which line the vasculature and supply oxygen, nutrients, and circulating cells, are particularly important. Their integrin-matrix interactions are modulated by extracellular matrix remodelling, thereby enhancing angiogenesis during the repair process (Agyare, Osafo, & Boakye, 2018; Lindley, Stojadinovic, Pastar,

Tomic-Canic, & surgery, 2016; Yussof, Omar, Pai, & Sood, 2012).

Growth factor activities in normal wound healing

Growth factors are essential regulators of the wound healing process, coordinating the transition from the inflammatory phase to tissue repair. They not only modulate immune defense mechanisms during inflammation but also initiate the proliferative phase by stimulating key cellular activities, including migration, proliferation, angiogenesis, and tissue formation (Werner & Grose, 2003).

These mediators, secreted by endothelial cells, fibroblasts, keratinocytes, macrophages, and neutrophils, play critical roles in wound repair. Among the most important are platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and transforming growth factor- β (TGF- β). In normal wound healing, the levels of these growth factors are upregulated to facilitate tissue regeneration (Barrientos et al., 2008).

During controlled inflammation, PDGF released by macrophages stimulates collagen synthesis, a key event in wound closure. Numerous studies have shown that PDGF not only enhances cell proliferation but also modulates inflammatory responses, thereby supporting skin regeneration [34]. Drawina et al. reported that elevated PDGF expression was strongly associated with accelerated wound closure in non-diabetic animal models with full-thickness wounds. The authors proposed that PDGF promotes wound repair by activating pathways such as MAPK, which stimulate cell proliferation and new tissue formation, ultimately contributing to faster wound closure (Drawina et al., 2022).

Connective tissue growth factor (CTGF), a cysteine-rich peptide with biological and immunological similarities to PDGF, also plays a vital role in tissue repair. It regulates cell

adhesion and migration, stimulates fibroblast proliferation, and promotes extracellular matrix production and granulation tissue formation (Leask & Abraham, 2004). A study on diabetic mice with full-thickness cutaneous wounds demonstrated that topical application of recombinant human CTGF significantly accelerated epithelial closure compared to untreated diabetic controls. The authors attributed this effect to enhanced collagen deposition at the wound site, which increased wound stiffness and strength, thereby facilitating improved healing (Henshaw, Boughton, Lo, McLennan, & Twigg, 2015).

The growth factor basic fibroblast growth factor (bFGF) is a potent mitogen that regulates proteins responsible for stimulating the proliferation of multiple cell types, particularly endothelial and fibroblast cells (Matsumoto et al., 2013). bFGF plays a critical role in accelerating wound healing by promoting neovascularisation, enhancing angiogenesis, and increasing collagenase synthesis (Nakamichi et al., 2016). Huang et al. demonstrated that FGFs influence the proliferative phase of diabetic wounds in mice by facilitating angiogenesis and epithelial formation, thereby significantly accelerating tissue regeneration while reducing scar formation (C. Huang et al., 2016; Liu, Liu, Deng, Li, & Nie, 2021). Clinical studies further support these findings, showing that the topical administration of bFGF—commercially available in Japan—effectively enhances wound healing outcomes (Akita, Akino, Imaizumi, & Hirano, 2005; Kinoshita et al., 2012).

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is another key angiogenic molecule that enhances capillary permeability. Forough et al. reported that increased VEGF expression improves angiogenesis and granulation tissue formation during wound healing (Shams et al., 2022). In diabetic mouse models, VEGF levels were found to be diminished; however,

treatment with the natural product Aloe vera elevated VEGF expression, leading to improved angiogenesis and significantly accelerated wound closure (Sargowo, Handaya, Widodo, Lyrawati, & Tjokroprawiro, 2011). The role of VEGF in wound healing is largely attributed to its ability to enhance vascular permeability through nitric oxide (NO)-mediated mechanisms, which cause plasma proteins such as fibrinogen to leak into the extracellular space. Fibrinogen is subsequently converted into a fibrin gel, providing a provisional matrix that supports cell migration and tissue repair (Bao et al., 2009).

Transforming growth factor- β (TGF- β) plays a pivotal role in wound healing by stimulating tissue repair and regeneration (Savari, Shafiei, Galehdari, & Kesmati, 2019). Following tissue injury, blood vessel disruption results in the extravasation of blood into the surrounding tissue. The coagulation cascade is then activated, leading to the formation of a fibrin clot that restores haemostasis and provides a temporary extracellular matrix scaffold to support cell migration. Platelets trapped within this clot release multiple growth factors, including TGF- β . This growth factor facilitates the recruitment of key wound-healing cells such as neutrophils, macrophages, and fibroblasts, thereby initiating subsequent stages of the repair process (Klass, Grobbelaar, & Rolfe). In a prior study, Roghaye et al. observed the TGF- β gene expression in healthy (non-diabetic) rats increased after being induced with treatment (Phenytoin). This could be attributed to TGF- β stimulating cells to enhance the synthesis of extracellular matrix proteins while simultaneously reducing collagen proteases (Savari et al., 2019).

Growth factor activities in abnormal wound healing

As research continues to elucidate their role in chronic wound pathophysiology, growth factors are increasingly recognised for their potential to enhance the effectiveness of wound care interventions (Park, Hwang, &

Yoon, 2017; Yamakawa, Hayashida, & trauma, 2019). In chronic wounds, growth factor signalling is often dysregulated, resulting in an inadequate physiological response that compromises healing. Evidence indicates that growth factor levels in chronic wounds are markedly lower compared to those in acute wounds (Koob et al., 2013).

Chronic wounds commonly fail to heal within the expected timeframe due to factors such as vascular insufficiency, infection, or pressure necrosis. Key angiogenic mediators such as bFGF and VEGF stimulate granulation tissue formation; however, when these growth factors are deficient, angiogenesis is impaired, granulation tissue becomes scarce, and the healing process is delayed (Yu et al., 2016). Experimental studies using full-thickness dorsal skin wounds in non-diabetic rats further demonstrated that chronic wounds exhibit significantly reduced bFGF expression compared with treated wounds. Subsequent angiogenesis assays confirmed diminished angiogenic activity in chronic wounds (Nakamichi et al., 2016).

Similarly, a review by Deng et al. reported that growth factor deficiency contributes to the development of chronic pressure ulcers. Specifically, levels of PDGF were significantly lower in chronic dermal ulcers compared with acute wounds. These findings suggest that insufficient growth factor activity is a major factor underlying chronic wound persistence. Thus, incorporating growth factors into wound treatment strategies may help prevent or slow the transition from acute to chronic wounds (Deng, Gould, & Ali, 2022).

Diabetic endothelial dysfunction

Endothelial cell dysfunction (ECD) refers to the disruption of normal endothelial functions, encompassing impaired barrier integrity, reduced vasodilation, alterations in proliferative capacity, diminished migration and tube formation, compromised angiogenic potential, weakened synthetic activity,

and decreased ability to prevent leukocyte adhesion and diapedesis. Multiple factors contribute to the development of ECD, including smoking, hypertension, diabetes, hyperlipidemia, obesity, hyperglycemia, advanced glycation end products (AGEs), and genetic predisposition (Kolluru, Bir, & Kevil, 2012). During endothelial injury, several changes are commonly observed, including impaired vasodilation, dysregulated production and secretion of bioactive substances, altered energy metabolism, and structural damage. The key pathophysiological mechanisms involved are oxidative stress and mitochondrial dysfunction, accompanied by inflammation, immune activation, increased vascular permeability, and barrier disruption (Xia et al., 2025).

Wound healing relies heavily on angiogenesis, and any disruption to this process can severely hinder tissue repair. In diabetic wounds, endothelial dysfunction plays a critical role by impairing angiogenesis and further complicating the healing process. Evidence shows that prolonged hyperglycemia in diabetic patients leads to reduced levels of key pro-angiogenic mediators, including vascular endothelial growth factor A (VEGFA), angiopoietin-1 (ANGPT1), and stromal cell-derived factor-1 (SDF-1). These factors are essential for endothelial cell proliferation, migration, and lumen formation (J. Zhang et al., 2025). According to Zhang et al., growth differentiation factor 11 (GDF11) promotes diabetic wound healing by mobilizing endothelial progenitor cells and enhancing neovascularization through activation of the HIF-1 α -VEGF/SDF-1 α signaling pathway. Likewise, transforming growth factor-beta 1 (TGF- β 1) serves as a key regulator of angiogenesis, facilitating wound repair by activating the Akt, Erk, and TGF- β /Smad3 signaling cascades (Zong et al., 2020).

Hyperglycemia hinders angiogenesis by decreasing nitric oxide (NO) production and elevating reactive oxygen species (ROS).

This oxidative stress compromises endothelial cell function, thereby limiting their angiogenic potential. Thus, restoring endothelial function to enhance angiogenesis may offer an effective therapeutic approach for promoting wound healing in diabetes (Malone-Povolny, Maloney, & Schoenfish, 2019; Xiong et al., 2023).

The role of medicinal plants in diabetic wound healing

Extensive research has demonstrated that natural products with anti-inflammatory, antioxidant, antibacterial, and collagen-stimulating properties exhibit promising wound-healing potential (Thakur et al., 2011). The phytochemical constituents of medicinal plants can promote tissue remodelling, epithelial regeneration, and angiogenesis, thereby supporting the repair of chronic wounds (Hsu, 2005; Thangapazham et al., 2016; Vanden Berghe & Haegeman, 2010). This is particularly relevant for diabetic foot ulcers, which often demand prolonged and costly treatments that place a significant socio-economic burden on both patients and healthcare systems (Shearer et al., 2003; Wild et al., 2004).

Given these challenges, the search for novel therapeutic agents derived from medicinal plants is crucial, not only to identify effective treatments but also to clarify their mechanisms of action in chronic wound repair (Jivad et al., 2016; Naji et al., 2017). Among these, mangosteen (*Garcinia mangostana*) has attracted considerable attention for its potential in diabetic wound healing.

In recent years, the number of studies investigating mangosteen's wound-healing effects has increased substantially. Of particular interest is α -mangostin, the most abundant xanthone in the mangosteen pericarp, which has been explored for its therapeutic properties. The present study focuses on evaluating the effect of α -mangostin on wound healing using an in vitro diabetic wound-healing model.

Mangosteen pericarp and wound healing

Mangosteen (*Garcinia mangostana* Linn., GML), commonly referred to as the “Queen of Fruits” (Figure 2.3), is a well-documented plant with notable biological and therapeutic potential. Traditionally, it has been used to manage infections, diarrhoea, dysentery, inflammation, skin disorders, and wounds (Obolskiy et al., 2009; Yang et al., 2017), and it continues to play an important role in traditional Chinese, Thai, and Ayurvedic medicine (Sultan et al., 2022).

The mangosteen pericarp is considered non-toxic and has shown no apparent adverse effects, making it a promising candidate for biomedical applications (S. Zhang et al., 2020). Recent studies have reported its positive impact on wound healing. For instance, Shafy et al. demonstrated that an ointment enriched with mangosteen pericarp accelerated wound closure and improved the tensile strength of healed skin in mice, with no observed side effects (Shafy, Jassim, & Mohammed, 2019). Figure 2 shows the image of the mangosteen pericarp.



Figure 2: The mangosteen fruit, also known as the “Queen of fruits”

The pericarp of mangosteen is particularly rich in phenolic compounds, notably xanthones, which are regarded as the primary bioactive constituents (Suttirak, Manurakchinakorn, & technology, 2014).

More than 50 different xanthone derivatives have been identified in the mangosteen pericarp (Pedraza-Chaverri, Cárdenas-Rodríguez, Orozco-Ibarra, Pérez-Rojas, & toxicology, 2008). These compounds display a wide range of biological activities, including antibacterial, antimalarial, anti-inflammatory, anticancer, antioxidant, and wound-healing effects (Febrina, Milanda, & Muchtaridi, 2018). Xanthones have been shown to promote fibroblast proliferation, an essential marker of effective wound healing, as increased fibroblast activity contributes to tissue repair and regeneration (Hanafiah, Abidin, Ilyas, Nainggolan, & Syamsudin, 2019).

Alpha(α)-mangostin

The most abundant xanthone present in the mangosteen pericarp is α-mangostin. Xanthones are organic polyphenolic compounds with the molecular formula $C_{13}H_8O_2$, characterised by a tricyclic skeleton that largely determines their biological activities. The specific properties of these molecules vary depending on the position and nature of functional groups and substitutions. Among the xanthone derivatives, α-, β-, and γ-mangostins have been the most extensively studied for their pharmacological potential, with α-mangostin being the predominant and most concentrated form found in the mangosteen pericarp (Jiang, Dai, & Li, 2004; K.-j. Zhang, Gu, Yang, Ming, & Wang, 2017). Figure 3 illustrates the chemical structure of α-mangostin.




Figure 3: Chemical structure for α-mangostin

Owing to its wide-ranging biological

and pharmacological activities, particularly in the context of wound management, α-mangostin has attracted significant interest in medicinal plant research (Rizaldy, Hartati, Nadhifa, & Fidrianny, 2021). Studies have demonstrated that α-mangostin exhibits stronger antioxidant activity than several well-known reference compounds. In addition, it possesses notable anti-inflammatory and antibacterial properties, further supporting its potential as a therapeutic agent for wound healing (Abate et al., 2022; McFarland, Hahn, Combs, & Supp).

Effect of α-mangostin in In-vitro study

A scratch assay investigation revealed that α-mangostin accelerates wound closure within 24 hours compared to the control group by enhancing both cell proliferation and migration. This assay, performed using a fibroblast cell line in a non-diabetic in vitro wound-healing model, suggests that α-mangostin may play a beneficial role in promoting wound repair (M. Siri Wattanasatorn, A. Itharat, P. Thongdeeying, B. J. E.-B. C. Ooraikul, & A. Medicine, 2020).

To illustrate the potential mechanisms underlying these findings, Figure 4 presents a schematic pathway summarising the proposed actions of α-mangostin across different phases of diabetic wound healing. The compound exerts anti-inflammatory effects by reducing IL-6 secretion, stimulates angiogenic growth factors and modulates matrix remodeling through MMP-9 suppression and TIMP-2 upregulation. Collectively, these actions contribute to enhanced endothelial repair, fibroblast proliferation, and overall wound closure.

Further evidence supports its anti-inflammatory potential, as α-mangostin has been shown to suppress the expression of pro-inflammatory cytokines, particularly IL-6 and IL-8, in human gingival fibroblasts (Yiemwattana & Kaomongkolgit, 2015).

To date, however, most studies

investigating α-mangostin have focused on its role in normal wound healing. Its specific effects on diabetic wound healing, especially regarding cell migration, inflammatory modulation, and growth factor regulation, remain poorly understood.

Diabetic wound healing with alpha (α)-mangostin




Figure 4: Proposed pathways of α-mangostin in diabetic wound healing

DISCUSSION

Although α-mangostin has shown strong biological activity, its use as a wound-healing therapy is still limited. For diabetic foot ulcers and other chronic wounds, effective formulations must improve skin absorption, stability, and controlled release. Delivery systems such as nanoemulsions, hydrogels, liposomes, and nanoparticle-based ointments can enhance the solubility and retention of α-mangostin at the wound site. Among these, natural polysaccharide-based hydrogels, such as gellan gum, are preferred because they keep the wound moist, adhere well to tissue, and are non-irritating. Recent studies reported that gellan gum (GG) hydrogel films containing α-mangostin showed good thickness, flexibility, and uniformity, along with strong antibacterial and antioxidant properties that increased with higher α-mangostin content. These features make GG hydrogels a promising option for delivering α-mangostin directly to

Table 1: *In-vitro* evidence of α-mangostin in wound healing

Study / Year	Model / Cell Type	Experimental Design / Treatment	Dose / Formulation	Measured Parameters	Main Findings
Ennesta Asri et al. (2021) (Asri11, Gustia, Sari, Wirman, & Aidi, 2025)	Human keloid fibroblasts	In-vitro treatment of keloid fibroblasts to evaluate collagen and TGF-β/SMAD pathway expression	20 μM α-mangostin	TGF-β1, SMAD3, Type I collagen (ELISA) and cell migration (scratch assay)	↓ TGF-β1 and SMAD3 expression and ↑ Type I collagen; reduced fibroblast proliferation and migration
Siriwattanasatorn et al. (2021)(M. Siriwattanasatorn, A. Itharat, P. Thongdeeying, B. J. E. B. C. Ooraikul, & A. Medicine, 2020)	Human dermal fibroblasts (scratch assay)	In-vitro wound-healing assay	1-10 μg/mL	% wound closure at 24 h, fibroblast proliferation	Accelerated scratch closure within 24 h and increased fibroblast proliferation
Yiemwattana et al. (2021) (Yiemwattana & Kaomongkolgit, 2015)	Fibroblast	Anti-inflammatory evaluation	0.5- 2.0 μg/mL	IL-6, IL-8 release	Significant suppression of IL-6 and IL-8 expression
Kevin L. McFarland et al. (2021) (McFarland et al.)	Human normal and keloid fibroblasts	Cells from three donors treated with α-mangostin; assessed for gene expression and protein secretion	5 μg/mL	COL1A1, MMP1, MMP3, MMP13, pro collagen I (gene expression)	↓ COL1A1 and pro-collagen I and ↑ MMP1 and MMP13 secretion
Menik Sayekti et al. (2022) (Sayekti et al., 2022)	Osteoblast 7F2 cell line	Four group post-test only design with LPS and α-mangostin induction	Not specified	IL-10 and Collagen 1A1 gene expression (qPCR)	↓ IL-10 expression (anti-inflammatory) and ↑ COL1A1 expression
Patrick et al. (2024) (Patrick et al., 2024)	Macrophage cells under glucose-induced stress	Comparative in-vitro diabetic wound model	2.5 μg/mL α-mangostin	PDGF, VEGF, MMP-9, IL-6, TIMP-2 levels	↑ PDGF & VEGF and ↓ MMP-9; no change in IL-6 or TIMP-2 vs. glucose controls

wounds for better healing and minimal side effects (Shahzad, Khan, & Khalid, 2025).

Previous studies have provided strong evidence supporting the efficacy of the NLC-P-αM (nanostructured lipid carrier-phytosomal α-mangostin) formulation in promoting diabetic wound healing. Across multiple biological assays, this nanoformulation consistently outperformed both the free α-mangostin compound and control treatments, meeting essential criteria for an effective wound-healing agent. Incorporating α-mangostin into lipid-based nanoparticles has been shown to markedly enhance its therapeutic stability, solubility, and bioavailability. Furthermore, in vivo diabetic wound-healing experiments demonstrated that NLC-P-αM significantly accelerated wound closure and facilitated advanced tissue regeneration, as evidenced by histological observations showing reduced inflammation

and restoration of normal skin architecture. Collectively, these findings indicate that NLC-P-αM represents a promising and innovative strategy for improving the clinical translation of α-mangostin in chronic and diabetic wound management (Suhandi et al., 2025).

From a safety perspective, at concentrations less than 10 μg/mL, α-mangostin has shown minimal cytotoxicity in fibroblast and macrophage models. Higher concentrations (>20 μM), particularly in fibroblast cells, have been linked to decreased cell viability and apoptotic induction. In order to balance pro-healing benefits and avoid delayed remodelling as a result of excessive matrix breakdown, dose optimisation is essential. Before moving on to human testing, toxicological profiling in skin irritation, sensitisation, and phototoxicity assays is advised (Asri11 et al., 2025; Patrick et al., 2024). Pharmacodynamically, rather than directly

stimulating angiogenesis, α-mangostin's antioxidant and anti-inflammatory properties seem to be the main source of its therapeutic benefits in diabetic wound models (Shahzad et al., 2025). The lack of in-vivo diabetes evidence calls for careful interpretation, despite the current in-vitro results showing up-regulation of PDGF and VEGF and down-regulation of MMP-9. Until they are confirmed in animal models of diabetes, mechanistic assertions beyond these measurable parameters especially those pertaining to growth-factor receptor signalling or molecular crosstalk should remain theoretical (Patrick et al., 2024). Furthermore, in vivo research should be carried out to verify the safety and therapeutic selectivity of α-mangostin before to moving forward with clinical use. Assessments of wound contraction, re-epithelialization, and skin cell migration should be part of these studies, along with an analysis of potential side effects including undesired apoptosis or altered collagen turnover. For α-mangostin to effectively promote healing without causing unfavourable scarring or fibrosis, preclinical validation is crucial (Sarian, Zulkefli, ZAIN, Maniam, & Fakurazi, 2023; Sawaragi et al., 2025).

CONCLUSION

Diabetic wounds are challenging to cure due to chronic inflammation, endothelial dysfunction, and decreased activity of growth factors as PDGF, VEGF, bFGF, CTGF, and TGF-β. There is limited information on the therapeutic efficacy of α-mangostin in this situation. However, current findings suggest it can promote cell migration, reduce pro-inflammatory cytokines, and restore growth-factor activity to facilitate angiogenesis and tissue healing. Further in-vivo investigations with diabetic animal models are required to corroborate these results, notably in terms of wound contraction, re-epithelialization, and long-term tissue remodelling. To ensure reproducibility and translational relevance, comprehensive preclinical testing should

consider safety, dosage optimisation, bioavailability, and formulation stability. Early-phase clinical trials can test the effectiveness of topical α-mangostin formulations in diabetic patients, with an emphasis on wound closure rate, infection control, and healing quality. Developing α-mangostin as an inexpensive, locally obtained natural-product therapy could enhance diabetic wound management, reduce healthcare expenses, and alleviate the burden of persistent, non-healing lesions like diabetic foot ulcers.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this paper.

ACKNOWLEDGEMENT

The authors would like to thank Universiti Malaysia Sabah (UMS) and Universiti Teknologi MARA (UiTM) for academic support during the preparation of this review.

REFERENCES

- Abate, M., Pagano, C., Masullo, M., Citro, M., Pisanti, S., Piacente, S., & Bifulco, M. (2022). Mangostanin, a xanthone derived from *Garcinia mangostana* fruit, exerts protective and reparative effects on oxidative damage in human keratinocytes. *Pharmaceuticals*, 15(1), 84.
- Agyare, C., Osafo, N., & Boakye, Y. D. (2018). Biomarkers of wound healing. In *Wound Healing-Current Perspectives*. IntechOpen.
- Akhhtar, S., Nasir, J. A., Ali, A., Asghar, M., Majeed, R., & Sarwar, A. (2022). Prevalence of type 2 diabetes and prediabetes in Malaysia: A systematic review and meta-analysis. *Plos One*, 17(1), e0263139.
- Akita, S., Akino, K., Imaizumi, T., & Hirano, A. (2005). Basic fibroblast growth factor improved the quality of skin grafting in burn patients. *Burns*, 31(7), 855–858.
- Asri, E., Gustia, R., Sari, I. I., Wirman, J., & Aidi, Y. (2025). The effect of alpha-mangostin on the expression of TGF-β1, SMAD3, type I collagen, proliferation, and migration of keloid fibroblasts.

- Aumiller, W. D., & Dollahite, H. A. (2015). Pathogenesis and management of diabetic foot ulcers. *Journal of the American Academy of Physician Assistants*, 28(5), 28–34.
- Baig, M. S., Banu, A., Zehravi, M., Rana, R., Burle, S. S., Khan, S. L., Rahman, M. H. (2022). An overview of diabetic foot ulcers and associated problems with special emphasis on treatments with antimicrobials. *Life*, 12(7), 1054.
- Bakker, K., Apelqvist, J., Lipsky, B. A., Van Netten, J. J., & Schaper, N. C. (2016). The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: Development of an evidence-based global consensus. *Diabetes/Metabolism Research and Reviews*, 32(1), 2–6.
- Bao, P., Kodra, A., Tomic-Canic, M., Golinko, M. S., Ehrlich, H. P., & Brem, H. (2009). The role of vascular endothelial growth factor in wound healing. *Journal of Surgical Research*, 153(2), 347–358.
- Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H., & Tomic-Canic, M. (2008). Growth factors and cytokines in wound healing. *Wound Repair and Regeneration*, 16(5), 585–601.
- Chavan, M. S. (2018). Prevalence and risk factors of diabetic foot ulcer at a tertiary care hospital among diabetic patients.
- Craus, S., Mula, A., & Coppini, D. V. (2023). The foot in diabetes. A reminder of an ever-present risk. *Clinical Medicine*.
- Demidova-Rice, T. N., Hamblin, M. R., & Herman, I. M. (2012). Acute and impaired wound healing: Pathophysiology and current methods for drug delivery, Part 1: Normal and chronic wounds: Biology, causes, and approaches to care. *Advances in Skin & Wound Care*, 25(7), 304–314.
- Deng, X., Gould, M., & Ali, M. A. (2022). A review of current advancements for wound healing: Biomaterial applications and medical devices. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*, 110(11), 2542–2573.
- Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes and diabetes-related complications. *Physical Therapy*, 88(11), 1254–1264.
- Drawina, P., Putra, A., Nasihun, T., Prajoko, Y. W., Dirja, B. T., & Amalina, N. D. (2022). Increased serial levels of platelet-derived growth factor using hypoxic mesenchymal stem cell-conditioned medium to promote closure acceleration in a full-thickness wound. *International Journal of Biomedicine*, 27(1), 36–42.
- Febrina, D., Milanda, T., & Muchtaridi, M. (2018). Pharmacological activity of *Garcinia mangostana* Linn.: A review.
- Ganasegeran, K., Hor, C. P., Jamil, M. F. A., Loh, H. C., Noor, J. M., Hamid, N. A., (2020). A systematic review of the economic burden of type 2 diabetes in Malaysia. *International Journal of Environmental Research and Public Health*, 17(16), 5723.
- Ganasegeran, K., Hor, C. P., Jamil, M. F. A., Suppiah, P. D., Noor, J. M., Hamid, N. A., ... (2021). Mapping the scientific landscape of diabetes research in Malaysia (2000–2018): A systematic scientometrics study. *International Journal of Environmental Research and Public Health*, 18(1), 318.
- Hanafiah, O. A., Abidin, T., Ilyas, S., Nainggolan, M., & Syamsudin, E. (2019). Wound healing activity of Binahong (*Anredera cordifolia* [Ten.] Steenis) leaf extract on NIH-3T3 fibroblast cells. *Journal of International Dental and Medical Research*, 12(3), 854–858.
- Henshaw, F. R., Boughton, P., Lo, L., McLennan, S. V., & Twigg, S. M. (2015). Topically applied connective tissue growth factor/CCN2 improves diabetic preclinical cutaneous wound healing: Potential role for CTGF in human diabetic foot ulcer healing. *Journal of Diabetes Research*, 2015.
- Hsu, S. (2005). Green tea and the skin. *Journal of the American Academy of Dermatology*, 52(6), 1049-1059.
- Huang, C., Orbay, H., Tobita, M., Miyamoto, M., Tabata, Y., Hyakusoku, H., (2016). Proapoptotic effect of controlled-release basic fibroblast growth factor on skin wound healing in a diabetic mouse model. *Wound Repair and Regeneration*, 24(1), 65–74.
- Huang, Z. H., Li, S. Q., Kou, Y., Huang, L., Yu, T., & Hu, A. (2019). Risk factors for the recurrence of diabetic foot ulcers among diabetic patients: A meta-analysis. *International Wound Journal*, 16(6), 1373-1382.
- Jalilian, M., Sarbarzeh, P. A., & Oubari, S. (2020). Factors related to severity of diabetic foot ulcer: A systematic review. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 13, 1835-1842.
- Jiang, D. J., Dai, Z., & Li, Y. J. (2004). Pharmacological effects of xanthenes as cardiovascular protective agents. *Cardiovascular Drug Reviews*, 22(2), 91–102.
- Jivad, N., Bahmani, M., & Asadi-Samani, M. (2016). A review of the most important medicinal plants effective on wound healing based on ethnobotanical evidence of Iran. *Der*

- Pharmacia Lettre, 8(2), 353–357.
- Kinoshita, N., Tsuda, M., Hamuy, R., Nakashima, M., Nakamura-Kurashige, T., Matsuu-Matsuyama, M., (2012). The usefulness of basic fibroblast growth factor for radiation-exposed tissue. *Wound Repair and Regeneration*, 20(1), 91–102.
- Klass, B. R., Grobbelaar, A. O., & Rolfe, K. J. Transforming growth factor β 1 signalling, wound healing and repair: A multifunctional cytokine with clinical implications for wound repair - a delicate balance.
- Kolluru, G. K., Bir, S. C., & Kevil, C. G. (2012). Endothelial dysfunction and diabetes: Effects on angiogenesis, vascular remodeling, and wound healing. *International Journal of Vascular Medicine*, 2012, 918267.
- Koob, T. J., Rennert, R., Zabek, N., Massee, M., Lim, J. J., Temenoff, J. S., Gurtner, G. C. (2013). Biological properties of dehydrated human amnion/chorion composite graft: Implications for chronic wound healing. *International Wound Journal*, 10(5), 493–500.
- Laing, T., Hanson, R., Chan, F., & Bouchier-Hayes, D. (2007). The role of endothelial dysfunction in the pathogenesis of impaired diabetic wound healing: A novel therapeutic target? *Medical Hypotheses*, 69(5), 1029–1031.
- Leask, A., & Abraham, D. J. (2004). TGF- β signaling and the fibrotic response. *The FASEB Journal*, 18(7), 816–827.
- Lim, J. Z. M., Ng, N. S. L., & Thomas, C. (2017). Prevention and treatment of diabetic foot ulcers. *Journal of the Royal Society of Medicine*, 110(3), 104–109.
- Lindley, L. E., Stojadinovic, O., Pastar, I., & Tomic-Canic, M. (2016). Biology and biomarkers for wound healing. *Plastic and Reconstructive Surgery*, 138(3), 185–285.
- Liu, Y., Liu, Y., Deng, J., Li, W., & Nie, X. (2021). Fibroblast growth factor in diabetic foot ulcer: Progress and therapeutic prospects. *Frontiers in Endocrinology*, 12, 744868.
- Magliano, D. J., Boyko, E. J., & International Diabetes Federation. (2021). Global picture. In *IDF Diabetes Atlas* (10th ed.). International Diabetes Federation.
- Malone-Povolny, M. J., Maloney, S. E., & Schoenfisch, M. H. (2019). Nitric oxide therapy for diabetic wound healing. *Advanced Healthcare Materials*, 8(12), 1801210.
- Matsumoto, S., Tanaka, R., Okada, K., Arita, K., Hyakusoku, H., Miyamoto, M., (2013). The effect of controlled-release basic fibroblast growth factor in wound healing: Histological analyses and clinical application. *Regeneses Open Surgery & General*, 1(6), e44.
- Maurya, M. K., Varma, R. K., Chaurasia, I. C., & Vishwakarma, R. (2019). A review literature on science of diabetes mellitus. *International Journal of Research and Reviews*, 6(2), 902–907.
- McFarland, K. L., Hahn, J. M., Combs, K. A., & Supp, D. M. Antiproliferative, proapoptotic, and potential antifibrotic effects of α -mangostin in fibroblasts from keloid lesions and normal skin.
- Naji, S., Zarei, L., Pourjabali, M., & Mohammadi, R. (2017). The extract of *Lycium depressum* Stocks enhances wound healing in streptozotocin-induced diabetic rats. *The International Journal of Lower Extremity Wounds*, 16(2), 85–93.
- Nakamichi, M., Akishima-Fukasawa, Y., Fujisawa, C., Mikami, T., Onishi, K., & Akasaka, Y. (2016). Basic fibroblast growth factor induces angiogenic properties of fibrocytes to stimulate vascular formation during wound healing. *The American Journal of Pathology*, 186(12), 3203–3216.
- Nussbaum, C., Bannenberg, S., Keul, P., Gräler, M. H., Goncalves-de-Albuquerque, C. F., Korhonen, H., Rohwedder, I. (2015). Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. *Nature Communications*, 6(1), 1–12.
- Obolskiy, D., Pischel, I., Siriwatanametanon, N., & Heinrich, M. (2009). *Garcinia mangostana* L.: A phytochemical and pharmacological review. *Phytotherapy Research*, 23(8), 1047–1065.
- Ontario Health Quality. (2017). Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: A health technology assessment. *Ontario Health Technology Assessment Series*, 17(5), 1–142.
- Pan, X., Kaminga, A. C., Wen, S. W., Acheampong, K., & Liu, A. (2019). Omentin-1 in diabetes mellitus: A systematic review and meta-analysis. *Plos One*, 14(12), e0226292.
- Panneerselvam, K., Vijayakumar, R., Raja, S. S., & Venkatesan, R. (2021). Isolation and identification of *Staphylococci* and *Pseudomonas* from diabetic foot ulcers in Perambalur District hospitals in Tamil Nadu. *Journal of Pharmaceutical Research International*, 33(13), 15–21.
- Park, J. W., Hwang, S. R., & Yoon, I. S. (2017). Advanced growth factor delivery systems in wound management and skin regeneration. *Molecules*, 22(8), 1259.
- Patrick, M., Zohdi, W. N. W. M., Abd Muid, S., & Omar,

- E. (2024). Alpha (α)-mangostin (xanthone of *Garcinia mangostana* L.): Augmenting macrophage activity for effective diabetic wound healing. *Trends in Sciences*, 21(10), 8254.
- Pedraza-Chaverri, J., Cárdenas-Rodríguez, N., Orozco-Ibarra, M., & Pérez-Rojas, J. M. (2008). Medicinal properties of mangosteen (*Garcinia mangostana*). *Food and Chemical Toxicology*, 46(10), 3227–3239.
- Raja, J. M., Maturana, M. A., Kayali, S., Khouzam, A., & Efeovbokhan, N. (2023). Diabetic foot ulcer: A comprehensive review of pathophysiology and management modalities. *World Journal of Clinical Cases*, 11(8), 1684–1706.
- Rizaldy, D., Hartati, R., Nadhifa, T., & Fidrianny, I. (2021). Chemical compounds and pharmacological activities of mangosteen (*Garcinia mangostana* L.): An updated review.
- Salazar-Gómez, A., & Alonso-Castro, A. J. (2022). Medicinal plants from Latin America with wound healing activity: Ethnomedicine, phytochemistry, preclinical and clinical studies—A review. *Plants*, 15(9), 1095.
- Sargowo, D., Handaya, A. Y., Widodo, M. A., Lyrwati, D., & Tjokropawiro, A. (2011). Aloe gel enhances angiogenesis in healing of diabetic wounds. *The Indonesian Biomedical Journal*, 3(3), 204–215.
- Savari, R., Shafiei, M., Galehdari, H., & Kesmati, M. (2019). Expression of VEGF and TGF- β genes in the skin wound-healing process induced by phenytoin in male rats. *Jundishapur Journal of Health Sciences*, 11(1).
- Sawaragi, E., Sakamoto, M., Katayama, Y., Kawabata, S., Somamoto, S., Noda, K., & Morimoto, N. (2025). A prospective multicenter phase III clinical trial evaluating the efficacy and safety of silk-elastin sponge in patients with skin defects. *Scientific Reports*, 15(1), 11279.
- Sayekti, M., Rizqiawan, A., Soesilawati, P., Mira, N. P., Kamadjaja, D. B., & Rahman, M. Z. (2022). The effect of alpha-mangostin on interleukin-10 and collagen 1A1 gene expression during the inflammatory process: An experimental in vitro study. *Journal of International Oral Health*, 14(4), 403–408.
- Shafy, G. M., Jassim, A. M. N., & Mohammed, M. T. (2019). Phytochemical, antioxidant, and anti-inflammatory properties of mangosteen (*Garcinia mangostana*) and its wound-healing ability. *Plant Archives*, 19(1), 665–673.
- Shahbazian, H., Yazdanpanah, L., & Latifi, S. M. (2013). Risk assessment of patients with diabetes for foot ulcers according to the risk classification consensus of the International Working Group on the Diabetic Foot. *Pakistan Journal of Medical Sciences*, 29(3), 730–734.
- Shahzad, S., Khan, I. U., & Khalid, I. (2025). α -Mangostin-encapsulated gellan gum membranes for enhanced antibacterial, anti-inflammatory, antioxidant, and wound-healing activity. *International Journal of Biological Macromolecules*, 308, 142493.
- Shams, F., Moravvej, H., Hosseinzadeh, S., Mostafavi, E., Bayat, H., Kazemi, B., ... Moosavian, H. (2022). Overexpression of VEGF in dermal fibroblast cells accelerates angiogenesis and wound-healing functions: In vitro and in vivo studies. *Scientific Reports*, 12(1), 18529.
- Shearer, A., Scuffham, P., Gordo, A., & Oglesby, A. (2003). Predicted costs and outcomes from reduced vibration detection in people with diabetes in the United States. *Diabetes Care*, 26(8), 2305–2310.
- Siriwattanasatorn, M., Itharat, A., Thongdeeying, P., & Ooraikul, B. (2020). In vitro wound-healing activities of three commonly used Thai medicinal plants and their three markers. *Evidence-Based Complementary and Alternative Medicine*, 2020, 6795383.
- Slavich, G. M., & Irwin, M. R. (2014). From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. *Psychological Bulletin*, 140(3), 774–815.
- Suhandi, C., Wilar, G., Mohammed, A. F. A., Mahmoud, S. A., Muchtaridi, M., Shamsuddin, S., ... Zuhendri, F. (2025). Propolis-based nanostructured lipid carrier of α -mangostin for promoting diabetic wound healing in alloxan-induced mice. *Journal of Inflammation Research*, 7443–7457.
- Sultan, O. S., Kantilal, H. K., Khoo, S. P., Davamani, A. F., Eusufzai, S. Z., Rashid, F., ... Alam, M. K. (2022). The potential of α -mangostin from *Garcinia mangostana* as an effective antimicrobial agent: A systematic review and meta-analysis. *Antibiotics*, 11(6), 717.
- Suttirak, W., & Manurakchinakorn, S. (2014). In vitro antioxidant properties of mangosteen peel extract. *Journal of Food Science and Technology*, 51(12), 3546–3558.
- Thakur, R., Jain, N., Pathak, R., & Sandhu, S. S. (2011). Practices in wound-healing studies of plants. *Evidence-Based Complementary and Alternative Medicine*, 2011, Article 438056.
- Thangapazham, R. L., Sharad, S., & Maheshwari, R. K. (2016). Phytochemicals in wound healing. *Advances in Wound Care*, 5(5), 230–241.
- Vanden Berghe, W., & Haegeman, G. (2010).

- Epigenetic remedies by dietary phytochemicals against inflammatory skin disorders: Myth or reality? *Current Drug Metabolism*, 11(5), 436–450.
- Werner, S., & Grose, R. (2003). Regulation of wound healing by growth factors and cytokines. *Physiological Reviews*, 83(3), 835–870.
- Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care*, 27(5), 1047–1053.
- Xia, T., Yu, J., Du, M., Chen, X., Wang, C., & Li, R. (2025). Vascular endothelial cell injury: Causes, molecular mechanisms, and treatments. *MedComm*, 6(2), e70057.
- Xiong, Y., Chu, X., Yu, T., Knoedler, S., Schroeter, A., Lu, L., Rinkevich, Y. (2023). Reactive oxygen species-scavenging nanosystems in the treatment of diabetic wounds. *Advanced Healthcare Materials*, 12(25), 2300779.
- Yamakawa, S., & Hayashida, K. (2019). Advances in surgical applications of growth factors for wound healing. *Burns & Trauma*, 7, Article 10.
- Yang, R., Li, P., Li, N., Zhang, Q., Bai, X., Wang, L., Yan, J. (2017). Xanthonenes from the pericarp of *Garcinia mangostana*. *Molecules*, 22(5), 683.
- Yazdanpanah, L., Shahbazian, H., Nazari, I., Hesam, S., Ahmadi, F., Cheraghian, B., (2018). Risk factors associated with diabetic foot ulcer-free survival in patients with diabetes. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 12(6), 1039–1043.
- Yiemwattana, I., & Kaomongkolgit, R. (2015). Alpha-mangostin suppresses interleukin-6 and interleukin-8 expression in *Porphyromonas gingivalis* lipopolysaccharide-stimulated human gingival fibroblasts. *Odontology*, 103(3), 348–355.
- Yu, H., Peng, J., Xu, Y., Chang, J., & Li, H. (2016). Bioglass-activated skin tissue engineering constructs for wound healing. *ACS Applied Materials & Interfaces*, 8(1), 703–715.
- Yun, L. S., Hassan, Y., Aziz, N. A., Awaisu, A., & Ghazali, R. (2007). A comparison of knowledge of diabetes mellitus between patients with diabetes and healthy adults: A survey from northern Malaysia. *Patient Education and Counseling*, 69(1–3), 47–54.
- Yussof, S. J. M., Omar, E., Pai, D. R., & Sood, S. (2012). Cellular events and biomarkers of wound healing. *Indian Journal of Plastic Surgery*, 45(2), 220–228.
- Zhang, J., Li, W., Liu, Y., Zheng, J., Liu, G., He, M., Liang, G. (2025). OTUD1 delays wound healing by regulating endothelial function and angiogenesis in diabetic mice. *Journal of Advanced Research*. Advance online publication.
- Zhang, K.-J., Gu, Q.-L., Yang, K., Ming, X.-J., & Wang, J.-X. (2017). Anticarcinogenic effects of α-mangostin: A review. *Planta Medica*, 83(3–4), 188–202.
- Zhang, S., Li, Z., Wang, X., An, L., Bao, J., Zhang, J., Tuerhong, M. (2020). Isolation, structural elucidation, and immunoregulatory properties of an arabinofuranan from the rinds of *Garcinia mangostana*. *Carbohydrate Polymers*, 246, 116567.
- Zong, J., Jiang, J., Shi, P., Liu, J., Wang, W., Li, B., ... Bi, L. (2020). Fatty acid extracts facilitate cutaneous wound healing by activating AKT, ERK, and TGF-β/Smad3 signalling and promoting angiogenesis. *American Journal of Translational Research*, 12(2), 478–492.